| Literature DB >> 35195258 |
Jeffrey W Tyner1,2, Franziska Haderk3,4,5, Anbarasu Kumaraswamy6, Linda B Baughn7, Brian Van Ness8, Song Liu9, Himangi Marathe9, Joshi J Alumkal6, Trever G Bivona3,4,5, Keith Syson Chan10,11, Brian J Druker1,2, Alan D Hutson9, Peter S Nelson12,13, Charles L Sawyers14,15, Christopher D Willey16.
Abstract
Decades of research into the molecular mechanisms of cancer and the development of novel therapeutics have yielded a number of remarkable successes. However, our ability to broadly assign effective, rationally targeted therapies in a personalized manner remains elusive for many patients, and drug resistance persists as a major problem. This is in part due to the well-documented heterogeneity of cancer, including the diversity of tumor cell lineages and cell states, the spectrum of somatic mutations, the complexity of microenvironments, and immune-suppressive features and immune repertoires, which collectively require numerous different therapeutic approaches. Here, we describe a framework to understand the types and biological causes of resistance, providing translational opportunities to tackle drug resistance by rational therapeutic strategies. ©2022 The Authors; Published by the American Association for Cancer Research.Entities:
Mesh:
Year: 2022 PMID: 35195258 PMCID: PMC9018544 DOI: 10.1158/0008-5472.CAN-21-3695
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 13.312